News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

1606 Corp Now Trading under Ticker CBDW, Management Announces First Acquisition

1606 Corp

McapMediaWire -- 1606 Corp (OTC: CBDW ), an acquisition-based CBD product distribution company, announced that the company has successfully started trading on the OTC Market under the Ticker Symbol of CBDW. 1606 Corp’s S-1 registration statement became effective on January 22, 2022 and began trading on the OTC Market on January 17th, 2023. CBDW is a ticker symbol that embodies the business model of 1606 Corp and highlights management's goal to build a product-driven CBD-Wellness company. CBD.Inc and 1606 Corp. look to accumulate a diverse portfolio of CBD products and companies nationwide. The business model will achieve management goals by consolidating the fragmented CBD industry via acquisitions. The Ticker symbol CBDW will provide market recognition of these goals and the company's business model. "It’s always been a critical component of trading on the public markets for companies to utilize a stock symbol that reinforces the mission of the company. We purposefully requested the ticker symbol "CBDW" because that ticker represents us as a business. Our core focus is on buying companies with great wellness products and brands that embody the benefits of CBD, and the ticker says all of that in just four letters." said Greg Lambrecht, CEO, and Chairman of 1606 Corp. 1606 Corp (OTC: CBDW) has signed a letter of intent (LOI) to purchase 51% of Brio Nutrition’s ( https://brionutrition.com / ), a profitable CBD development and distribution company. Brio Nutrition's has agreed to an LOI with 1606 Corp and filed for an audit on September 30th, 2022, which is still pending. Upon completion of the audit, a combination of stock and cash, totaling USD 600,000.00, will be transferred, and the transaction will be complete. Brio Nutrition Revenue (unaudited) 2021 $763,079 2020 $1,116,336 "Brio Nutrition's is the first of many acquisitions we intend on closing this year. The CBD market is quite fragmented and growing so we're on a mission to consolidate the industry by purchasing companies with strong product brands and established distribution. We'll use these accumulated outlets to cross-pollinate our product line. It's going to be the key to our success" Said Greg Lambrecht CEO of 1606 Corp DBA CBD Inc. About Brio Nutrition; Brio Nutrition is a premium CBD product developer, supplier, and wellness company focused on providing the highest quality hemp derivatives and formulations for people and pets. Brio Nutrition develops and supplies CBD gummies, topicals, capsules, topicals and oils to assist.in treating pain, anxiety, sleep performance, and depression for all those in need. The products developed and distributed by Brio provide holistic solutions designed to ensure a higher quality of life for all living beings. About 1606 Corporation Management; Greg Lambrecht has successfully taken three companies public. He is starting with premium cigars International which went to the NASDAQ in 1997. Again in 2011, Mr. Lambrecht took Singlepoint public on the OTC Markets. Singlepoint is pursuing a move up the NASDAQ as well. He will take the knowledge and expertise learned in both these endeavors into the new public entity 1606 Corp. About 1606 Corp; In April 2021, 1606 Corp. was spun off from Singlepoint Inc. (OTCQB: SING).1606 has been able to develop smokable hemp brands to add to 1606 original, including Truz and CBD Singlez ( www.1606hemp.com ) The company intends to acquire Companies in the CBD, including brands, distribution, retail outlets, and manufacturing. 1606 Corp. was awarded the ticker symbol CBDW on January 12th, 2022. Industry Information; The Cannabidiol (CBD) market accounted for USD 12.8 billion in 2021 and is estimated to grow with a 21.7% CAGR between 2022 and 2028, according to Grand view research (link). The global cannabidiol (CBD) market size was valued at $5.18 billion in 2021 and is expected to expand, at a compounded annual growth rate (CAGR) of 16.8% from 2022 to 2030. Cannabidiol (CBD) is a chemical compound that is found in the cannabis Sativa plant, and is extracted from hemp or cannabis, generally from hemp due to its naturally high cannabidiol (CBD) content.. Forward-Looking Statements This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief, or current expectations of 1606 Corp (the "Company"), its directors, or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the Company's control and which could, and likely will materially affect actual results, levels of activity, performance, or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Contact: Greg Lambrecht greg@1606corp.com CBD.inc Austen Lambrecht austen@1606corp.com CBD.inc 888-223-9510 Company Websites; www.1606hemp.com www.CBD.Inc Contact Details Greg Lambrecht greg@1606corp.com Austen Lambrecht austen@1606corp.com

January 26, 2023 08:00 AM Eastern Standard Time

Article thumbnail News Release

Spectral MD "very excited" about 2023

Spectral MD Holdings Ltd

Spectral MD Holdings Ltd (AIM:SMD) chief operating officer Niko Pagoulatos speaks to Proactive's Thomas Warner about his plans for the company during 2023. He reveals more details about the timeline for the DeepView Wound Imaging System and explains what milestones investors can expect, adding that he is "very excited" about what the year has in store. Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 26, 2023 03:00 AM Eastern Standard Time

Video
Article thumbnail News Release

Oxford Cannabinoid Technologies with "lots to look forward to" after interims

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) CEO Clarissa Sowemimo-Coker speaks to Proactive's Thomas Warner following the release of interim results for the six months ending 31st October 2022. Sowemimo-Coker looks ahead to what investors can expect during the first half, saying that there is "plenty to look forward to." She also reveals details of the current state of the company's finances. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 26, 2023 03:00 AM Eastern Standard Time

Video
Article thumbnail News Release

Roquefort Therapeutics demonstrates initial safety in two antibody programmes

Roquefort Therapeutics PLC

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) CEO Ajan Reginald speaks to Proactive's Thomas Warner after announcing that the company's ROQ-A1 and ROQ-A2 Midkine (MDK) antibody programmes have successfully demonstrated safety in pre-clinical studies. Reginald says that he's now hoping to "move rapidly into efficacy testing". Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 26, 2023 03:00 AM Eastern Standard Time

Video
Article thumbnail News Release

Primary Health Properties seizes "good opportunity" in Ireland

Primary Health Properties PLC

Primary Health Properties PLC (LSE:PHP, OTC:PHPRF) (PHP) founder and CEO Harry Hyman talks to Proactive's Thomas Warner after announcing the acquisition of Irish property management business Axis Technical Services Limited, with an agreement to develop sites in Ireland signed with related company Axis Health Care. The acquisition is part of a wider strategy to expand into the Irish healthcare sector, with Hyman saying that there is a "good opportunity" for the company to "carry on deploying capital prudently and sensibly in Ireland." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 26, 2023 03:00 AM Eastern Standard Time

Video
Article thumbnail News Release

hVIVO announces "record results" for 2022

hVIVO PLC

hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Proactive's Thomas Warner after releasing a trading update for 2022 that shows the specialist contract research organisation achieved "record results" in 2022. Khan reveals the reasons for the improvement in the performance of the business and looks ahead to what investors can expect from hVIVO for the rest of 2023. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 26, 2023 03:00 AM Eastern Standard Time

Video
Article thumbnail News Release

Survey reveals the leading causes of weight gain — and it’s not just food or lack of exercise

Able

Rising global overweight and obesity rates are typically attributed to overconsumption and a lack of movement. However, new research highlights the far more complex combination of lifestyle choices and challenges that cause weight gain. In a survey 1 of over 100,000 users of Able, a health coaching app that tailors personal programs to each individual to help them achieve their goals, users most commonly attributed their weight gain to stress (24.5%), family life (12.5%), medication (11.7%) and work (10.9%). Likewise, 57.7% of overweight people get just five to seven hours of sleep each night, with poor sleep quality a major risk factor for obesity. Data shows that diet does play a role, but more so due to what people consume, rather than how much. Some 79.3% of respondents stated that they eat three or fewer meals daily. However, 26.8% most commonly consume sweet foods throughout the day. Likewise, 19.2% regularly eat fried food, 16.6% consume caffeine and 9.3% drink alcohol, all of which have been linked to weight gain. The survey also found that many users signing up to Able had debilitating health conditions that can impact the ability to lose weight. Some 12% of females and 2% of males reported suffering from depression and anxiety. Likewise, 6% of women and 1% of men had insomnia, while 4% of women and 1% of men reported being asthmatic. In addition, 6% of women reported hormonal issues. “The human body is intricate and reaching our optimal weight is never so straightforward as moving more and eating less,” Roman Taranov, CEO and founder of Able said. “As this data shows, it's often not for lack of trying, but to achieve results you really must consider each person’s body, mind and situation. With an action plan that targets the specific factors that impact an individual, no reasonable weight loss goal is unachievable.” Hoping to improve their health (23.9%), feel good (21.5%) and live longer (16.7%), almost a third of users had tried gym exercise. Similarly, 24.4% had tried a restrictive diet and a further 21.2% attempted a fitness-focused diet. However, losing weight requires addressing the various factors that impact our body, from diet to rest to medication, while staying motivated and working around our busy schedules. The survey data was collected from more than 100,000 people who submitted responses to the intake questionnaire for Able's weight loss program. Overall, 57% were aged over 50 and 20% under 30. Women made up 81% of respondents. 1 Research findings based on a survey questionnaire to members of the Able community that was completed between December 2022 and January 2023. 102,361 adults aged between 18 and 48 based around the world responded to the survey. About Able Able is a digitally native health and wellness platform that provides access to high-quality, comprehensive weight care from start to finish, at the cost of an affordable monthly subscription. Founded in 2021, Able’s weight loss program works because it treats the whole person, addressing every factor that impacts weight. Able clients achieve lasting results by making better food and movement choices, with the support and accountability of a personal health coach within the app who guides them in adapting their lifestyle and habits. Contact Details Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://ableapp.com/

January 25, 2023 08:00 AM Pacific Standard Time

Image
Article thumbnail News Release

UCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023

UC Asset LP

McapMediawire -- UC Asset LP (OTCQB: UCASU ) management announces that the company has jump-started its plan to up-list to a major exchange, probably NASDAQ or NYSE, after it had put on hold this plan for about six months. “Twelve months ago, we kicked off our campaign for an up-listing, and we had made solid progress toward this goal, before the dramatic change of macro-economy and stock market in general made it undesirable for us to continue the process,” explains Larry Wu, founder of UC Asset. “So we decided to freeze the plan by the end of July, 2022.” "Despite that there are still concerns about macro-economy, as well as about the stock market, we at UC Asset have been doing well, and we have decided not to let macro-economic factors to stop us from pursuing a faster growth,” exclaims Wu. Wu refers to the track record of the company, particularly the growth of its profit. According to its most recent annual report, the company posted net income of $0.13 per share for the year of 2021, which represented 400% growth over its $0.03 per share net income for the year of 2020. Looking forward, the management projects a $0.20 per share gross profit for the year of 2023. Last year, the company distributed a cash dividend of $0.10 per share to its common shareholders. Management has confirmed that it will make more dividend distribution in the future. Wu admits that the company is currently too small to justify an up-listing, as a major exchange listing will be more expensive, and will remarkably increase administration cost. Those extra cost will be difficult for a small company like UC Asset to absorb. “In order to have a meaningful uplisting, we need to increase the size of the company to at least $20 million, preferably over $30 million," says Wu. "Our management team has an established strategy to growth. We have identified deal pipelines with great potential, mostly of cannabis properties, for a potential portfolio expansion of $10 - $ 30 million. We have the right team to manage them. We are confident we are able to achieve the economy scale with additional capital," Wu shares. For this purpose, UC Asset plans to launch a SPO (secondary public offering) to raise $10 – 20 million. Wu indicates that it may also conduct a PIPE (private investment in public equity) raise prior to the SPO to raise $2 – 5 million. “All the fund-raising will not dilute the equity of current shareholders, as our bylaw expressly prohibits the company from issuing any stocks at a price lower than the company’s net equity per share,” asserts Wu. “Particularly, we will NEVER take any investments of toxic manner, such as convertible notes of variable conversion ratios.” "We have been very disciplined in issuing shares," continues Wu. " Our total issued and outstanding shares have actually decreased since our IPO, from over 5.6 million shares to less than 5.5 million shares. And last year we cancelled all our preferred units of a total number of 166,667 shares. In short, the supply of our shares is very limited, and we have adequate room to support our growth plan." About UC Asset LP UC Asset LP is a limited partnership formed for the purpose of investing in real estate with innovative strategies. For more information about UC Asset, please visit: www.ucasset.com Disclaimer: This News Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any these statements. You are cautioned not to place undue reliance on any those forward-looking statements. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements after the date of this news release. None of such forward-looking statements should be regarded as a representation by us or any other person that the objectives and plans set forth in this News Release will be achieved or be executed. For More Information Contact: IR@UCasset.com Contact Details Larry Wu IR@UCasset.com Company Website http://www.ucasset.com/

January 25, 2023 10:59 AM Eastern Standard Time

Article thumbnail News Release

ST. MATTHEWS SPECIALTY PHARMACY EXPANDS HEPATITIS C MEDICATION ACCESSIBILITY TO HELP COMBAT “SILENT EPIDEMIC”

Cordant Health Solutions

St. Matthews Specialty Pharmacy ( stmatthewsrx.com ), a Cordant Health Solutions® company, is partnering with healthcare providers to make an impact on reducing barriers to treatment and increasing access to medication for hepatitis C virus (HCV) in conjunction with the treatment of substance use disorder (SUD). There are approximately 42,500 people living with hepatitis C in Kentucky. Often called a “silent epidemic,” cases of acute HCV have increased 124% in the U.S. since 2013 and 16% from 2019 to 2020 alone. HCV is highly preventable and curable in more than 95% of people in as few as 8–12 weeks with direct-acting antiviral (DAA) medications, yet more than half of people who become infected with the virus will develop a chronic infection that can cause liver damage, cirrhosis, liver cancer, and death. HCV disproportionately affects marginalized groups, including people with substance use disorder. Approximately 70% of patients on opioid agonist treatment (OAT) and an estimated 40% of people who inject drugs are HCV positive. St. Matthews Specialty Pharmacy has a unique integrated care model led by pharmacists and technicians with advanced experience in managing co-existing and co-occurring health disorders, such as hepatitis, in individuals suffering from substance use disorder. Patients at St. Matthews Specialty Pharmacy are enrolled in a patient management plan where they are provided one-on-one individualized disease state education, drug therapy management and medication counseling. This personalized approach to care using customized pharmacist intervention increases treatment adherence and improves success of patients reaching their health goals. “We have been curing patients with HCV since 1998,” said Dr. Bennet Cecil, founder of the Hepatitis C Treatment Center in Louisville. “We have been able to reach many more Kentuckians by coordinating our efforts with St. Matthews Specialty Pharmacy and substance abuse specialty clinics. This coordination produces many more cured patients than the previous models of care.” “There are so many obstacles that prevent people from seeking treatment for substance use disorder,” said Bob Mann, executive vice president of Cordant Health Solutions’ integrated services. “Many experience homelessness, are uninsured, have limited or no transportation available to get to appointments, or don’t have a doctor or know how to find one. But once they take that first step, we need to take that opportunity to treat the whole patient, not just an individual condition. We work with clinicians to coordinate pharmacy services for substance use disorder and other diseases like hepatitis to bring extended care to patients at the same time and place they’re receiving their other treatments.” St. Matthews Pharmacy also offers a managed addiction treatment pharmacy program, which delivers medication to patients at their doctor’s office at the time of their appointment, eliminating additional transportation and time challenges and helping to increase retention in their treatment program. According to the Substance Abuse and Mental Health Services Administration (SAMHSA ), addiction treatment facilities are well-positioned to greatly impact access to screening and treatment of HCV positive patients. Additionally, the American Society of Addiction Medicine (ASAM) states “integration of service delivery, addressing the unique needs of addiction patients, including HCV treatment, is strongly encouraged.” About Cordant Health Solutions® Cordant Health Solutions® (cordantsolutions.com) provides innovative solutions for clinicians, organizations and payers involved with substance use disorder, pain management and criminal justice cases to provide accurate, actionable results to hold patients accountable, reduce risk and improve patient outcomes. A leader in quality standards, Cordant integrates its unique specialized pharmacy services for medication-assisted treatment and associated behavioral health conditions with drug testing options that include monitoring and risk assessment tools to improve patient accountability and optimize quality of life. For media inquiries, contact Kim Kudasik, Senior Marketing Manager, kkudasik@cordanths.com. ### Contact Details Kim Kudasik +1 303-842-7975 kkudasik@cordanths.com

January 25, 2023 06:00 AM Eastern Standard Time

1 ... 163164165166167 ... 302